Élan shares have fallen another 20% in Dublin as the fallout from the company's decision to withdraw a multiple sclerosis drug continues.
The company's value is being hit after it announced that a second patient using its MS drug in a clinical trial had been confirmed with a rare and often fatal infection known as PML.
In a statement, Elan and its partner in the manufacture of Tysabri, Biogen Idec, confirmed they were co-operating with the US Securities and Exchange Commission in connection with the voluntary suspension in the marketing of the drug.
Sales of the drug were suspended on Monday after one patient died from PML while participating in a long-term clinical trial of the drug.
Élan shares plunged 70% on Monday when news of the drug withdrawal broke.
